-0.0700   (-1.89%)
Pre-market: .00 -3.63 (-100.00%)
Volume (24h) Market Cap. Day Range 52w Range
11,770 144.02M 3.63 - 3.79 3.63 - 22.20
Sep-30-20 08:05PM GENFIT: First Half-Year 2020 Financial Report and New Corporate StrategyGlobeNewswire
06:30PM Genfit SA to Host Earnings CallACCESSWIRE
Sep-28-20 06:00AM GENFIT and LabCorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver DiseaseGlobeNewswire
Sep-25-20 11:37AM The Daily Biotech Pulse: Novavax Advances Vaccine, Marinus Gets Nod For Late-Stage Study, 3 IPOsBenzinga
Sep-24-20 08:10PM GENFIT Announces First Patient First Visit for ELATIVE Phase 3 Study Evaluating Elafibranor in PBCGlobeNewswire
Sep-22-20 08:10PM GENFIT To Announce First Half-Year 2020 Financial Results and New Corporate Strategy on September 30, 2020GlobeNewswire
Sep-02-20 03:20PM Intercept Pharmaceuticals Will Lay Off a Quarter of Its Staff as NASH Dream
Aug-26-20 08:10PM GENFIT Announces Two Oral Presentations at the Digital International Liver Congress™ 2020GlobeNewswire
Aug-05-20 11:35AM The Daily Biotech Pulse: Novavax Vaccine Data, Aerpio Gets $5.1M Funding For COVID Trial, Rigel Gains Big On EarningsBenzinga
06:30AM GENFIT Announces Pivotal Publication of NIS4™ Technology to Identify Patients with At-Risk NASH in The Lancet Gastroenterology & HepatologyGlobeNewswire
Jul-23-20 03:02PM A Top Contender in the Race for a NASH Drug Drops
Jul-22-20 08:05PM GENFIT: Provides Initial Update on Corporate StrategyGlobeNewswire
Jul-10-20 08:05PM GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et CommercialGlobeNewswire
Jun-30-20 02:29PM Intercept Slumps as the FDA Issues CRL to NASH CandidateZacks
Jun-29-20 08:05PM Intercept Shares Tumble on NASH
Jun-15-20 09:19PM Many 'Ifs' Surrounding Viking
Jun-10-20 12:36PM Is Genfit (GNFT) Stock a Solid Choice Right NowZacks
May-26-20 05:19PM Intercept Down on Postponement of AdCom Meet for NASH DrugZacks
May-14-20 09:31PM After Drug Failure, Genfit's Cupboard Is Nearly
May-12-20 06:20PM Here's Why Shares of Durect Jumped Higher TodayMotley Fool
05:17PM Why Genfit Is Cratering TodayMotley Fool
May-12-20 03:03PM GNFT Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Genfit SA and Encourages Investors to Contact the FirmACCESSWIRE
12:06PM The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma EarningsBenzinga
May-12-20 08:39AM Genfit Craters 49% On Failed NASH Trial; Top Analyst ‘Not Surprised’SmarterAnalyst
08:35AM Genfit Plunges After Liver Medicine Falls Short in StudyBloomberg
May-11-20 09:52PM This Biotech Just Lost Half Its Value After A Key Hepatitis Drug FailedInvestor's Business Daily
Apr-17-20 12:43PM Why Genfit (GNFT) Stock Might be a Great PickZacks
Apr-11-20 06:32AM Genfit SA (EPA:GNFT) Just Released Its Full-Year Earnings: Here's What Analysts ThinkSimply Wall St.
Mar-30-20 10:06PM FDA Decisions on 5 Drugs Expected in 2nd
Mar-04-20 09:26PM SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Genfit SA - GNFTGlobeNewswire
Mar-02-20 03:25PM GNFT ALERT - Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Genfit SA And Encourages Investors to Contact the FirmACCESSWIRE
Feb-26-20 08:06PM GNFT ALERT - Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Genfit SAPR Newswire
Feb-21-20 04:57PM Genfit Delays Data From Liver-Disease Study. Analysts Are Confused and the Stock Is
Feb-17-20 10:35AM Imagine Owning Genfit (EPA:GNFT) And Trying To Stomach The 76% Share Price DropSimply Wall St.
Jan-08-20 12:37PM Will Genfit Continue to Surge Higher?Zacks
Dec-22-19 10:32PM Hedge Funds Aren’t Crazy About Genfit SA (GNFT) AnymoreInsider Monkey
Dec-10-19 08:36PM Genfit Hopes to Buck the Odds With NASH
Nov-26-19 01:06PM The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH DrugBenzinga
Nov-18-19 07:57AM Is Genfit SA (EPA:GNFT) A Volatile Stock?Simply Wall St.
Nov-09-19 07:58PM Hedge Funds Are Dumping Genfit SA (GNFT)Insider Monkey
Oct-03-19 01:29PM Is Genfit (EPA:GNFT) A Risky Investment?Simply Wall St.
Aug-19-19 06:45PM Obesity Epidemic Leads To A New Problem — And It Could Be Worth BillionsInvestor's Business Daily
Aug-13-19 06:10AM Did Changing Sentiment Drive Genfit's (EPA:GNFT) Share Price Down By 47%?Simply Wall St.
Jul-08-19 08:32AM Could Genfit SA's (EPA:GNFT) Investor Composition Influence The Stock Price?Simply Wall St.
Jun-29-19 10:18PM Hedge Funds Have Never Been This Bullish On Genfit SA (GNFT)Insider Monkey
Jun-25-19 11:15AM The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology PartnershipBenzinga
Jun-17-19 05:50PM ContraVir Moves Higher After NASH Drug Shows 100% Efficacy In Fibrosis PreventionBenzinga
Jun-12-19 11:34AM The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For AratanaBenzinga
May-09-19 06:00PM Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues BeatZacks
May-02-19 07:43PM Genfit, Cymbay Hope to Crack Large Liver Disease
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic test for the identification of patients with NASH; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.
Cap:    |  Volume (24h):